Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Apr 27, 2022 5:17pm
167 Views
Post# 34636999

RE:RE:We knew that was coming !!!

RE:RE:We knew that was coming !!!
themagicbox wrote: Honestly, if Otena hits the market today, I would have no issues taking the drug now. The SE we've seen thus far is hardly comparable to whats on the market. IMO its all about appeasing the FDA regulartors, or as Stauffer calls them, "masters". 

But Mugs have you read anything into new h2s moeities? I am thinking they create a new dosing regimin like we discussed before or use a moeity that delivers h2s more slowly. 


Not specifically, but there is new chemistry for IBD and I think there are a few different angles being studied there.  We just don't know the details.

I also think what they learn from the IBD chemistry will serve as a blueprint for developing 340.

But ... 

On the release side - I'm still betting that we don't need to worry about it for 346 - chronic.
They have ideas on the regimen side, convincing enough that they've taken a patent out on it.

Will see.






<< Previous
Bullboard Posts
Next >>